All In Biotech

NDA 021812 · Kenvue Brands

Men'S Rogaine

Minoxidil · Topical · Arteriolar Vasodilator

Last checked: Nov 20, 2026Latest source record: Jan 14, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2006

Jan 20, 2006

Approved uses

2

Original approval plus efficacy supplements

Registered trials

93

21 Phase 3, 12 recruiting

FAERS reports

44,887

4,801 serious, 454 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Nov 13, 2024.

Use to regrow hair on the top of the scalp (see pictures on side of this carton)

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

2 products under this application
  • MEN'S ROGAINE · MINOXIDIL 5% · AEROSOL, FOAM, TOPICAL · Over-the-counter
  • WOMEN'S ROGAINE · MINOXIDIL 5% · AEROSOL, FOAM, TOPICAL · Over-the-counter

Clinical trials

Interventional ClinicalTrials.gov studies with "Minoxidil" as an intervention, any sponsor and status, largest first.

All 93 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • adverse drug reaction8,621
  • drug ineffective7,781
  • alopecia3,745
  • application site pruritus2,976
  • off label use2,224
  • application site irritation1,441
  • application site pain1,432
  • overdose1,413
  • hair texture abnormal1,402
  • headache1,355
  • incorrect dose administered1,331
  • inappropriate schedule of product administration1,196

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
200495
2005122
2006128
200789
2008113
2009130
2010149
2011167
2012219
2013152
2014196
20152,015
20162,755
20172,715
20182,301
20192,081
20203,225
20215,591
20228,463
20236,201
20243,687
20252,671
20261,622

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 380 on PubMed

Sponsor: Kenvue Brands · Also marketed as Women'S Rogaine

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.